474706-74-6

Basic information

• Product Name: 6-broMo-3-iodoH-iMidazo[1,2-a]pyridine
• Synonyms: 6-broMo-3-iodoH-iMidazo[1,2-a]pyridine;IMidazo[1,2-a]pyridine, 6-broMo-3-iodo-;6-BroMo-3-iodoiMidazo[1,2-a]pyridine
• CAS NO: 474706-74-6
• Molecular Formula: C₇H₄BrIN₂
• Molecular Weight: 326.91723
• EINECS: 678-205-5
• Product Categories: Heterocycle-Pyridine series
• Mol File: 474706-74-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 209℃
• Appearance: /
• Density: 2.41
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.45±0.50(Predicted)
• CAS DataBase Reference: 6-broMo-3-iodoH-iMidazo[1,2-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMo-3-iodoH-iMidazo[1,2-a]pyridine(474706-74-6)
• EPA Substance Registry System: 6-broMo-3-iodoH-iMidazo[1,2-a]pyridine(474706-74-6)

Safety Data

• Hazardous Substances Data: 474706-74-6(Hazardous Substances Data)

Usage

General Description

6-Bromo-3-iodoH-imidazo[1,2-a]pyridine is a chemical compound with the molecular formula C7H4BrIN2. It belongs to the class of Heterocyclic Compounds and is a derivative of imidazo[1,2-a]pyridine. 6-broMo-3-iodoH-iMidazo[1,2-a]pyridine is widely used in the field of medicinal chemistry for the synthesis of various pharmaceuticals. It is known to exhibit biological activities and has been studied for its potential use in the treatment of various diseases. Additionally, it is used as a building block in organic synthesis to create new compounds with diverse properties and applications. Due to its versatile nature, 6-Bromo-3-iodoH-imidazo[1,2-a]pyridine is an important chemical in the field of drug discovery and development.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 6188-23-4 6-bromoimidazo[1,2-a]pyridine 

Downstream Products

• 1276110-19-0 N-(5-(3-(pyridin-3-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-benzenesulfonamide 
• 1233690-80-6 3-iodo-6-(trifluoromethyl)imidazo[1,2-a]pyridine 
• 1612185-51-9 6-bromo-3-(4-fluorophenyl)imidazo[1,2-a]pyridine 
• 1612185-30-4 3-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-3H-imidazol-4-yl]imidazo[1,2-a]pyridine 
• 1612185-10-0 3-(4-fluorophenyl)-6-[2-(4-fluorophenyl)-2H-pyrazol-3-yl]imidazo[1,2-a]pyridine 
• 1464155-66-5 4-(6-bromoimidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464152-71-3 (4-aminopiperidin-1-yl)(4-(3-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)phenyl)methanone 
• 1464158-76-6 tert-butyl 1-(4-(3-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)benzoyl)piperidin-4-ylcarbamate 
• 1464152-67-7 (4-amino-4-methylpiperidin-1-yl)(4-(3-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)phenyl)methanone 
• 1464158-68-6 tert-butyl 1-(4-(3-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)benzoyl)-4-methylpiperidin-4-ylcarbamate 
• 1464158-63-1 4-(3-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)benzoic acid 
• 1464158-58-4 ethyl 4-(3-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl)benzoate 
• 1464152-65-5 4-(6-(4-(4-methoxy-4-methylpiperidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464152-59-7 4-(6-(3-(piperazin-1-yl)-4-(piperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

PHOSPHOTIDYLINOSITOL 3-KINASE INHIBITORS

This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.